July 2, 2008
PEARL THERAPEUTICS CLOSES $18 MILLION FINANCING

June 23, 2008
RELYPSA - 2008 FIERCE 15

June 18, 2008
IKARIA'S INOFLO (NITRIC OXIDE) FOR INHALATION TO BE OFFICIALLY APPROVED IN JAPAN

June 10, 2008
SYNOSIA BEGINS PROOF-OF-MECHANISM TRIAL FOR NITISINONE

June 3, 2008
ENTREMED PRESENTS MCK-1 PHASE 2 DATA AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

May 19, 2008
IKARIA COMPLETES DOSING OF PHASE 1A CLINICAL STUDY FOR IK-1001 (SODIUM SULFIDE) FOR INJECTION

May 8, 2008
DANA-FARBER CANCER INSTITUTE COMMENCES PHASE 1 TRIAL WITH ENTREMED'S SELECTIVE KINASE INHIBITOR

April 28, 2008
KALOBIOS COMPLETES PATIENT DOSING IN ITS U.S. PHASE 1 TRIAL OF ITS THIRD DRUG CANDIDATE, KB003

April 15, 2008
ANAPHORE, INC. RECEIVES $8M FINANCING

April 9, 2008
ENTREMED ACHIEVES A KEY MILESTONE THROUGH INITIATION OF ENMD-2076 CLINICAL PROGRAM

April 2, 2008
ENTREMED COMMENCES CONTINUOUS DOSING CLINICAL TRIAL FOR MKC-1

March 31, 2008
KALOBIOS INITIATES PHASE 1/2 TRIAL OF HUMANEERED(TM) MONOCLONAL ANTIBODY KB001 FOR TREATMENT OF PSEUDOMONAS INFECTIONS IN CYCTIC FIBROSIS PATIENTS

March 31, 2008
SYNOSIA STARTS PHASE II EFFICACY TRIAL FOR RUFINAMIDE

March 10, 2008
KALOBIOS INITIATES PHASE 1/2 TRIAL OF KBOO2 ENGINEERED MONOCLONAL ANTIBODY IN PERSISTENT ASTHMA

March 6, 2008
MARCADIA BIOTECH, INC. AND MERCK & CO., INC. ENTER STRATEGIC COLLABORATION

February 28, 2008
PHASERX ANNOUNCES SEED FINANCING

February 26, 2008
AMBRX APPOINTS DOUGLAS AXELROD SENIOR VICE PRESIDENT FOR CLINICAL RESEARCH AND DEVELOPMENT

February 20, 2008
5AM VENTURES ANNOUNCES EXPANSION OF INVESTMENT TEAM: NAMES RICHARD ULEVITCH VENTURE PARTNER; PROMOTES KEVIN FORREST AND ANDREW MCMILLAN TO PRINCIPAL

February 4, 2008
SYNOSIA THERAPEUTICS APPOINTS CHIEF FINANCIAL OFFICER TO NEW COMPANY HEADQUARTERS IN SWITZERLAND

January 29, 2008
CHEMDIV, INC. AND ACHAOGEN ENTER INTO A DISCOVERY COLLABORATION

January 29, 2008
KALOBIOS STRENGHTENS DEVELOPMENT EXPERTISE WITH ADDITIONS TO SENIOR MANAGEMENT TEAM

January 28, 2008
KALOBIOS ELECTS DENISE M. GILBERT, PH.D. TO THE BOARD OF DIRECTORS

January 23, 2008
ENTREMED COMMENCES PHASE 2 STUDY WITH MKC-1 IN OVARIAN/ENDOMETRIAL CANCERS

January 22, 2008
ROBERT CONNELLY JOINS PULMATRIX AS CEO

January 22, 2008
SYNOSIA ANNOUNCES ENCOURAGING RESULTS OF PROOF-OF-CONCEPT CLINICAL TRIAL FOR EPILEPSY DRUG RUFINAMIDE AS A TREATMENT FOR MOOD DISORDERS

January 9, 2008
IKARIA APPOINTS DANIEL TASSE AS PRESIDENT AND CHIEF EXECUTIVE OFFICER